Jade Biosciences, Inc. Investing Cash Flow
Jade Biosciences, Inc. (JBIO) reported Investing Cash Flow of -$106.10 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-10
- Jade Biosciences, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was -$97.63M.
- Jade Biosciences, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was -$8.47M, a 165.91% decline year-over-year.
- Jade Biosciences, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was -$98.16M, a 847.67% decline year-over-year.
- Jade Biosciences, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was -$148.71M.
- Jade Biosciences, Inc. net cash provided by (used in) investing activities for fiscal 2025 was -$247.01M, a 540.85% decline from fiscal 2024.
- Jade Biosciences, Inc. net cash provided by (used in) investing activities for fiscal 2024 was $56.03M, a 371.78% increase from fiscal 2023.
- Jade Biosciences, Inc. net cash provided by (used in) investing activities for fiscal 2023 was $11.88M, a 71.47% increase from fiscal 2022.
- Jade Biosciences, Inc. net cash provided by (used in) investing activities for fiscal 2022 was $6.93M.
| Period end | Net Cash Provided by (Used in) Investing Activities 0 month | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$97.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$106.10M 10-Q · filed 2026-08-10 | -$204.26M derived: sum of 3 quarters · filed 2026-08-10 | -$352.97M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2026-03-31 | -$8.47M 10-Q · filed 2026-05-07 | -$106.63M derived: sum of 2 quarters · filed 2026-05-07 | -$255.34M derived: sum of 3 quarters · filed 2026-05-07 | -$268.33M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-12-31 | -$98.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | -$246.87M derived: sum of 2 quarters · filed 2026-03-06 | -$259.86M derived: sum of 3 quarters · filed 2026-08-10 | -$247.01M 10-K · filed 2026-03-06 | |
| 2025-09-30 | -$148.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$161.69M derived: sum of 2 quarters · filed 2026-08-10 | -$148.84M 10-Q · filed 2025-11-14 | -$135.72M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-06-30 | -$12.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$136.00K 10-Q · filed 2026-08-10 | $12.99M derived: sum of 3 quarters · filed 2026-08-10 | $12.99M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-03-31 | $12.85M 10-Q · filed 2025-04-25 | $25.98M derived: sum of 2 quarters · filed 2025-04-25 | $25.98M derived: sum of 3 quarters · filed 2025-11-14 | $43.98M derived: sum of 4 quarters · filed 2025-11-14 | |
| 2024-12-31 | $13.13M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $13.13M derived: sum of 2 quarters · filed 2025-11-14 | $31.13M derived: sum of 3 quarters · filed 2025-11-14 | $56.03M 10-K · filed 2025-03-27 | |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-14 | $18.00M derived: sum of 2 quarters · filed 2025-11-14 | $42.90M 10-Q · filed 2024-11-12 | $32.48M derived: sum of 4 quarters · filed 2025-11-14 | |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-13 | $18.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $26.83M 10-Q · filed 2024-08-12 | $32.48M derived: sum of 3 quarters · filed 2025-04-25 | $19.35M derived: sum of 4 quarters · filed 2025-04-25 |
| 2024-03-31 | $8.83M 10-Q · filed 2025-04-25 | $14.48M derived: sum of 2 quarters · filed 2025-04-25 | $1.35M derived: sum of 3 quarters · filed 2025-04-25 | $5.33M derived: sum of 4 quarters · filed 2025-04-25 | |
| 2023-12-31 | $5.65M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$7.48M derived: sum of 2 quarters · filed 2025-03-27 | -$3.50M derived: sum of 3 quarters · filed 2025-03-27 | $11.88M 10-K · filed 2025-03-27 | |
| 2023-09-30 | -$13.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$9.15M derived: sum of 2 quarters · filed 2024-11-12 | $6.23M 10-Q · filed 2024-11-12 | $20.71M derived: sum of 4 quarters · filed 2024-11-12 | |
| 2023-06-30 | $3.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $19.36M 10-Q · filed 2024-08-12 | $33.84M derived: sum of 3 quarters · filed 2024-08-12 | $38.49M derived: sum of 4 quarters · filed 2024-08-12 | |
| 2023-03-31 | $15.38M 10-Q · filed 2024-05-13 | $29.86M derived: sum of 2 quarters · filed 2024-05-13 | $34.51M derived: sum of 3 quarters · filed 2024-05-13 | $42.70M derived: sum of 4 quarters · filed 2024-05-13 | |
| 2022-12-31 | $14.49M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $19.13M derived: sum of 2 quarters · filed 2024-03-25 | $27.32M derived: sum of 3 quarters · filed 2024-03-25 | $6.93M 10-K · filed 2024-03-25 | |
| 2022-09-30 | $4.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $12.84M derived: sum of 2 quarters · filed 2023-11-13 | -$7.56M 10-Q · filed 2023-11-13 | -$120.90M derived: sum of 4 quarters · filed 2023-11-13 | |
| 2022-06-30 | $8.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$12.21M 10-Q · filed 2023-08-14 | -$125.54M derived: sum of 3 quarters · filed 2023-08-14 | -$125.60M derived: sum of 4 quarters · filed 2023-08-14 | |
| 2022-03-31 | -$20.40M 10-Q · filed 2023-05-15 | -$133.74M derived: sum of 2 quarters · filed 2023-05-15 | -$133.79M derived: sum of 3 quarters · filed 2023-05-15 | -$133.79M derived: sum of 4 quarters · filed 2023-05-15 | |
| 2021-12-31 | -$113.34M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | -$113.39M derived: sum of 2 quarters · filed 2023-03-29 | -$113.39M derived: sum of 3 quarters · filed 2023-03-29 | -$113.43M 10-K · filed 2023-03-29 | |
| 2021-09-30 | -$56.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$56.00K derived: sum of 2 quarters · filed 2022-11-14 | -$96.00K 10-Q · filed 2022-11-14 | ||
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$40.00K 10-Q · filed 2022-08-15 | |||
| 2021-03-31 | -$40.00K 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |